Teva Pharmaceuticals International, a unit of Teva Pharmaceutical Industries (TEVA), has entered into a strategic collaboration with Klinge Biopharma GmbH and Formycon AG for the semi-exclusive commercialization of FYB203, Formycon's biosimilar candidate to Eylea in Europe, excluding Italy, and in Israel. Klinge has in-licensed the global commercialization rights to FYB203 from Formycon.
Teva will lead the commercialization of FYB203 in the designated regions, to be marketed under the brand name AHZANTIVE3. Klinge will receive milestone payments and a portion from the products revenue.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.